EGFr-Positive Cancers

Phase Ib/IIa Results of C225 Cancer Therapeutic Reported

Published in Cancer Weekly, June 3rd, 1996

ImClone Systems Inc., New York, New York, announced the results of the Phase Ib/IIa multi-center dose-escalation study of C225, an epidermal growth factor receptor (EGFr) antagonist, at 32nd annual meeting of the American Society of Clinical Oncology (ASCO), held in Philadelphia, Pennsylvania, May 18-21, 1996.

In patients with advanced cancer and over-expression of EGFr (EGFr-positive cancers), seven out of a total of 17 patients demonstrated stable disease after four weeks, and subsequently received additional treatments on a weekly basis for another eight weeks. No major toxicities were noted in this study.

"The results from our Phase Ib/IIa...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1996-06-03)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry